Cargando…
Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China
HLA-haploidentical hematopoietic stem cell transplantation (HSCT) may be an option for severe aplastic anemia (SAA) patients. However, to date, no large-sample studies have been performed to determine which types of SAA patients are suitable for HLA-haploidentical HSCT. We retrospectively studied 18...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802708/ https://www.ncbi.nlm.nih.gov/pubmed/29410500 http://dx.doi.org/10.1038/s41598-018-20853-9 |
_version_ | 1783298570480254976 |
---|---|
author | Zeng, Yunjing Wang, Sanbin Wang, Jishi Liu, Li Su, Yi Lu, Zhixiang Zhang, Xuemei Zhang, Yanqi Zhong, Jiang Fan Peng, Lihui Liu, Qiang Lu, Yinghao Gao, Lei Zhang, Xi |
author_facet | Zeng, Yunjing Wang, Sanbin Wang, Jishi Liu, Li Su, Yi Lu, Zhixiang Zhang, Xuemei Zhang, Yanqi Zhong, Jiang Fan Peng, Lihui Liu, Qiang Lu, Yinghao Gao, Lei Zhang, Xi |
author_sort | Zeng, Yunjing |
collection | PubMed |
description | HLA-haploidentical hematopoietic stem cell transplantation (HSCT) may be an option for severe aplastic anemia (SAA) patients. However, to date, no large-sample studies have been performed to determine which types of SAA patients are suitable for HLA-haploidentical HSCT. We retrospectively studied 189 consecutive patients with SAA who underwent HLA-identical or HLA-haploidentical HSCT at seven transplant centers in China. Propensity score matching (PSM) was applied in this study to reduce the influence of potential confounders. The 5-year overall survival (OS) rate was 72.0% in the HLA-haploidentical group and 76.5% in the HLA-identical group. The median time to achieve engraftment and the incidence of acute GVHD/chronic GVHD were not significantly different between the two groups. In the subgroup analysis, the outcome of patients older than 40 years in the HLA-haploidentical group was significantly poorer than that of patients younger than 40 years in the same group and that of patients older than 40 years in the HLA-identical group. Based on the above results, we suggest that HLA-haploidentical relative HSCT should be considered as a valid alternative option for patients younger than 40 years with SAA for whom no matched sibling donor is available. |
format | Online Article Text |
id | pubmed-5802708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-58027082018-02-14 Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China Zeng, Yunjing Wang, Sanbin Wang, Jishi Liu, Li Su, Yi Lu, Zhixiang Zhang, Xuemei Zhang, Yanqi Zhong, Jiang Fan Peng, Lihui Liu, Qiang Lu, Yinghao Gao, Lei Zhang, Xi Sci Rep Article HLA-haploidentical hematopoietic stem cell transplantation (HSCT) may be an option for severe aplastic anemia (SAA) patients. However, to date, no large-sample studies have been performed to determine which types of SAA patients are suitable for HLA-haploidentical HSCT. We retrospectively studied 189 consecutive patients with SAA who underwent HLA-identical or HLA-haploidentical HSCT at seven transplant centers in China. Propensity score matching (PSM) was applied in this study to reduce the influence of potential confounders. The 5-year overall survival (OS) rate was 72.0% in the HLA-haploidentical group and 76.5% in the HLA-identical group. The median time to achieve engraftment and the incidence of acute GVHD/chronic GVHD were not significantly different between the two groups. In the subgroup analysis, the outcome of patients older than 40 years in the HLA-haploidentical group was significantly poorer than that of patients younger than 40 years in the same group and that of patients older than 40 years in the HLA-identical group. Based on the above results, we suggest that HLA-haploidentical relative HSCT should be considered as a valid alternative option for patients younger than 40 years with SAA for whom no matched sibling donor is available. Nature Publishing Group UK 2018-02-06 /pmc/articles/PMC5802708/ /pubmed/29410500 http://dx.doi.org/10.1038/s41598-018-20853-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Zeng, Yunjing Wang, Sanbin Wang, Jishi Liu, Li Su, Yi Lu, Zhixiang Zhang, Xuemei Zhang, Yanqi Zhong, Jiang Fan Peng, Lihui Liu, Qiang Lu, Yinghao Gao, Lei Zhang, Xi Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China |
title | Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China |
title_full | Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China |
title_fullStr | Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China |
title_full_unstemmed | Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China |
title_short | Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China |
title_sort | optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: a large-sample study from china |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802708/ https://www.ncbi.nlm.nih.gov/pubmed/29410500 http://dx.doi.org/10.1038/s41598-018-20853-9 |
work_keys_str_mv | AT zengyunjing optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT wangsanbin optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT wangjishi optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT liuli optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT suyi optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT luzhixiang optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT zhangxuemei optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT zhangyanqi optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT zhongjiangfan optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT penglihui optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT liuqiang optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT luyinghao optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT gaolei optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina AT zhangxi optimaldonorforsevereaplasticanemiapatientrequiringallogeneichematopoieticstemcelltransplantationalargesamplestudyfromchina |